Formycon (FYB.DE) Stock Price
Formycon Price
Revenue has compounded at 61.9% per year over the past 16 years to 44.48 M EUR. Earnings per share have grown at 54.8% per year over the last 9 years. Formycon's net margin stands at -145.5%, down from -36.3% several years earlier. Analysts set a median price target of 40.80 EUR, implying 114.1% above the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus.
Formycon stock price
Formycon business model & stock analysis
Frequently asked questions about Formycon
The business model of Formycon AG is focused on the development and commercialization of high-quality biosimilar medicines. As a biopharmaceutical company, Formycon specializes in the production of affordable and safe alternatives to expensive biological drugs. By leveraging its proprietary technology and extensive expertise, Formycon aims to address unmet medical needs and improve patient access to therapies. The company collaborates with strategic partners to carry out the research, development, and clinical trials required for regulatory approval. Through its commitment to innovation and cost-effectiveness, Formycon AG strives to contribute to the betterment of healthcare systems worldwide.
Formycon AG is primarily active in the pharmaceutical industry.
The main competitors of Formycon AG in the market include major pharmaceutical companies such as Novartis, Pfizer, Roche, and Sanofi.
Formycon AG is a renowned biopharmaceutical company based in Germany. Established in 2010, the company specializes in the development and production of biosimilars, which are biological drugs highly similar to existing approved products. As a significant player in the industry, Formycon AG aims to make healthcare more affordable and accessible by providing cost-effective biosimilar solutions. The company's expertise lies in the fields of rheumatology, ophthalmology, and oncology, among others. With a strong commitment to research and innovation, Formycon AG has successfully built a robust pipeline of biosimilar candidates and established partnerships with major pharmaceutical companies.
Formycon AG, a renowned pharmaceutical company, has achieved several significant milestones. Notably, the company has successfully developed and commercialized cost-effective biosimilar medicines for various diseases. Formycon AG has gained regulatory approvals for several products, including biosimilar candidates for eye diseases, such as ranibizumab and aflibercept. Moreover, the company has entered into strategic partnerships with prominent pharmaceutical companies, expanding its global reach and market presence. Formycon AG's commitment to innovation and extensive research has driven its success in delivering high-quality and affordable treatments. With its steadfast dedication, Formycon AG continues to redefine healthcare standards and improve patient access to life-saving medications.
Formycon AG is primarily present in Germany, where it is headquartered. As a leading biopharmaceutical company, Formycon operates in various regions across the globe. However, its primary focus remains on the German market, leveraging its expertise in biosimilar drugs. With a strong presence in Germany, Formycon AG aims to contribute to the development and accessibility of high-quality and affordable medicines for patients.
Formycon AG represents values of innovation, excellence, and sustainability in the pharmaceutical industry. Committed to advancing biosimilar drug development, Formycon AG focuses on enhancing patient access to affordable treatments. The company strives to create high-quality and safe biosimilars, providing patients with effective alternatives to expensive originator drugs. Formycon AG's corporate philosophy is rooted in their dedication to delivering high-value propositions that benefit both patients and healthcare systems. By leveraging their expertise in molecular biology and biotechnology, Formycon AG aims to address the unmet medical needs and improve the quality of life for patients worldwide.
Analysts currently set an average price target of 50.43 EUR for the Formycon stock (median: 40.80 EUR), implying +164.6 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Formycon stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Formycon to generate revenue of 80.77 M EUR and earnings per share of 0.03 EUR.
The Formycon share (FYB.DE) is listed on 8 stock exchanges, including: London (0W4N.L), SIX (Zürich) (FYB.SW), XETRA (FYB.DE), Frankfurt (FYB.F), München (FYB.MU), Düsseldorf (FYB.DU), Hamburg (FYB.HM).
The Formycon AG is a biotechnology company specializing in biosimilars. Their business model is to offer more affordable versions of biotechnologically manufactured medicines already on the market. Biosimilars are biologically produced medicines that have similar active ingredients to already approved original preparations and have the same therapeutic effect. The company specializes in developing biosimilars for various therapy areas such as oncology, rheumatology, ophthalmology, and neurology. They focus particularly on established brand products with high value potential. The company conducts research and development in collaboration with partners and clients from the pharmaceutical industry and utilizes its biotechnology expertise in areas such as cell line development, fermentation processes, and the purification of active ingredients. In addition to development, the company aims to successfully market its biosimilars by partnering with established pharmaceutical companies for global distribution channels and rapid entry into key markets. The Formycon AG is currently working on several biosimilars in different stages of clinical development. They also offer consulting services related to biosimilars, leveraging their extensive biotechnology knowledge to support customers in bringing biosimilars to market. In summary, Formycon AG offers a comprehensive range of services including biosimilar development, marketing and distribution support, and biotechnology consulting. Through their focus on biosimilars and partnerships with established pharmaceutical companies, they can quickly and successfully enter the market and establish themselves as a leading provider.
The expected revenue of Formycon is 80.77 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Formycon is 524,754.00 EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Formycon is currently 641.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Formycon stock.
The price-to-sales ratio (P/S) of Formycon is currently 4.17. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Formycon stock.
The Eulerpool Quality Score for Formycon is 2/10.
The ISIN of Formycon is DE000A1EWVY8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Formycon is A1EWVY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Formycon is FYB.DE. The ticker symbol is used to trade Formycon shares on the stock exchange.
Formycon stock
Formycon Peer Group
Formycon Ticker
Formycon FIGI
All fundamentals and in-depth analysis of Formycon
Our stock analysis for Formycon stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formycon. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.